Behavioral Finance

May 29, 2026

Slide titled Incremental Return on Invested Capital with a four-bar chart on a dark blue background.

Incremental Return on Invested Capital: The Mauboussin-Greenwald Compounder Test That Reveals Whether Every New Rupee of Capital Earns Its Keep

Headline RoIC describes legacy capital; Incremental RoIC describes the most recent rupees deployed. The Mauboussin-Greenwald compounder test, explained step-by-step with audited Indian disclosures.

May 28, 2026

Article header: Sloan's Accrual Anomaly: Why High-Accrual Stocks Underperform, with intro paragraph and author byline on a beige page.

Sloan’s Accrual Anomaly: The 1996 Accounting Review Discovery That High-Accrual Stocks Underperform — And Why the Cash-Backed Earnings Test Is the Single Most Powerful Forensic Filter for Indian Long-Term Investors

Richard Sloan 1996 Accounting Review discovery on high-accrual underperformance and the cash-backed earnings test for Indian long-term investors.

May 27, 2026

Left dark blue panel showing the DIR title and a box labeled Formula with cash, marketable securities and net receivables, plus daily operating cash outflow; right side presents a cream background infographic titled Defensive Interval Ratio with a five-bar chart (Red

Defensive Interval Ratio: The Forensic Liquidity Metric That Reveals How Many Days a Business Can Survive Without Selling Inventory or Receiving New Revenue

How to read the Defensive Interval Ratio — the forensic liquidity metric that counts days of survival without selling inventory or receiving new revenue, illustrated with audited FY25 markers from a disciplined Indian specialty-biotech operator.

May 26, 2026

Year Pat Cagr Cover 960x750 - Multibagger Shares

10-Year PAT CAGR: The Bottom-Line Compounding Test Every Indian Long-Term Investor Must Master

Learn how to read 10-Year PAT CAGR, the single most concentrated measure of a decade of bottom-line compounding — with Indian-context benchmarks, four diagnostic archetypes, six classic traps, and a worked illustration from Titan Biotech's FY25 audited disclosures.

+91-8448836436